Hydroxyurea use during pregnancy: A case report in sickle cell disease and review of the literature
β Scribed by Diav-Citrin, Orna; Hunnisett, Laura; Sher, Graham D.; Koren, Gideon
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 19 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
β¦ Synopsis
A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age. The pregnancy and delivery were complicated by vaso-oclusive crises. A healthy male infant was born at 39 weeks with no evidence of congenital malformations. A literature review, including this case, suggests that the risk of hydroxyurea exposure during in pregnancy may have been overestimated. Further studies are required to determine its safety in pregnancy.
π SIMILAR VOLUMES
Secondary gout is a recognized complication of several hematologic disorders, including many chronic hemolytic anemias characterized by increased purine metabolism. However, gouty arthritis has been described in only a few patients with hemoglobinopathies, and the identification of typical monosodiu
## Little is known about the use of monoamine oxidase inhibitors (MAOIs) during pregnancy and the postpartum period. We present a literature review with what we believe is the second case report of phenelzine exposure throughout pregnancy and the postpartum period. Potential indications for use and
Background. Granular cell tumor was first described by Abrikossoff in 1926. It is rare and usually presents as a benign solitary lesion. Multifocal and malignant forms are known to occur. Methods. This presentation illustrates an additional case of granular cell tumor. Clinical and histological fea